Evidence map›Paper›PMID 41249758›Full record

ArticleChinese journal of integrative medicine2026

Polysaccharide of Danggui Buxue Decoction Attenuates Colorectal Cancer via Modulating Intestinal Microflora and Metabolites.

Min Guo, Xin-Chi Zhang, Dong-Fei Guo, Sai-Xue Wei, Jian-Nan Cao, Xiao-Dong Li, De-Wen Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Min GuoLaboratory of Chinese Medicine, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou, 730050, China.
Xin-Chi ZhangGuangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd., Guangzhou, 510515, China.
Dong-Fei GuoEACHY Biopharmaceuticals Co., Ltd., Zhangjiagang, Jiangsu Province, 215600, China.
Sai-Xue WeiCollege of Pharmacy, Gansu University of Chinese Medicine, Lanzhou, 730000, China.
Jian-Nan CaoCollege of Pharmacy, Gansu University of Chinese Medicine, Lanzhou, 730000, China.
Xiao-Dong LiLaboratory of Chinese Medicine, Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou, 730050, China. li_xd2005@126.com.
De-Wen LiuExperimental Research Center, China Academy of Chinese Medical Sciences, Beijing, 100700, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo explore whether polysaccharide of Danggui Buxue Decoction (formula polysaccharide, FP) could attenuate colorectal cancer (CRC) via modulating intestinal microflora and metabolites.

methodsA total of 30 male C57BL/6 mice were randomly assigned to 3 groups according to body weight, including normal control, CRC model and FP groups (n=10). Dextran sulfate sodium and azoxymethane were used to induce CRC model. The mice in FP group were treated with FP [0.9 g/(kg·d)] for 8 weeks. Then the coloretal length, weight and tumors number of colorectal tissues were observed. Colonic tissues were stained with hematoxylin and eosin to evaluate the histological changes. Tight junction proteins including claudin 1 and zonula occludens-1 (ZO-1) were detected using immunohistochemistry. Serum concentrations of endothelial cell specific molecule-1 and carcino embryonic antigen were determined using enzyme-linked immunosorbent assays. Toll-like receptor 4 (TLR4)/nuclear transcription factor-κB (NF-κB) p65 signal-related mRNA and proteins expressions were detected using real-time polymerase chain reaction and Western blot, respectively. Feces samples were detected with 16S rRNA and liquid chromatography-mass spectrometry and non-targeted metabolomics sequencing was used to analyze the composition of intestinal microbiota and metabolic changes.

resultsFP significantly inhibited colorectal tumor growth, attenuated body weight loss, repaired colonic structure, improved intestinal barrier dysfunction, reduced colonic inflammatory cytokine levels and inhibited TLR4/NF-κB pathway related mRNA and protein expressions (all P<0.01). Moreover, FP altered the gut microbiota composition of CRC mice dramatically, characterized by a reduction of Firmicutes-Bacteroidetes ratio at the phylum level. FP suppressed Lachnospiraceae_NK4A136_group, Odoribacter and Romboutsia (P<0.05 or P<0.01), and elevated the abundance of Dubosiella, Candidatus_Saccharimonas and Alloprevotella at the genus level (P<0.01). Non-targeted metabolomics sequencing detected significant differences in metabolites, and the functions of differential metabolites were focused on regulating amino acid metabolism, lipid metabolism and metabolism of cofactors and vitamins.

conclusionsFP attenuates colonic injury and intestinal inflammatory response in CRC mice, repairs disrupted-intestinal microbiota, and improves metabolites. This research provides experimental basis for application of FP as a potential therapeutic agent for CRC.

Indexed as

Colorectal NeoplasmsDrugs, Chinese HerbalGastrointestinal MicrobiomePolysaccharidesAnimalsMaleMiceMice, Inbred C57BLSignal TransductionToll-Like Receptor 4danggui buxue decoctionDrugs, Chinese HerbalPolysaccharidesToll-Like Receptor 4Chinese medicinecolorectal cancerDanggui Buxue Decoctionintestinal microflorametabolitespolysaccharide

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.